The Cancer MoonShot 2020 program is one of the most comprehensive cancer collaborative initiatives launched to date, seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients.
This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in 20,000 patients at all stages of disease in 20 tumor types within the next 36 months.
These findings will inform Phase III trials and the aspirational moonshot to develop an effective vaccine-based immunotherapy to combat cancer by 2020.
It’s time to use all our knowledge and technology to radically change the way we treat cancer
Cancer MoonShot 2020 announced on Tuesday June 7, the formation of the Breast Cancer Working Group. The team consists of physicians, researchers and oncology professors from across the nation who have come together to focus their collective wisdom and expertise to identify and develop the most effective cancer-directed immunotherapy treatments for breast cancer.
And on Wednesday June 8, Cancer MoonShot 2020 announced the formation of the Head and Neck Working Group. The team consists of scientists, physicians, and oncology professors from across the nation who have come together to focus their collective wisdom and expertise to identify and develop the most effective cancer-directed immunotherapy treatments for Head and Neck cancers.
Experts within these groups will collaborate to develop clinical trial protocols, carefully studying elements such as standard of care, GPS Cancer test factors, patient selection, and appropriate combination immunotherapy approaches. GPS Cancer, offered by NantHealth, is a unique, comprehensive test integrating quantitative proteomics, and whole genome (DNA) and transcriptome (RNA) sequencing of tumor and normal germline samples to provide oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies and identify therapies that may have clinical benefit for the patient, including Quantitative Integrative Lifetime Trials (QUILT). GPS Cancer is performed in the CLIA-certified, CAP-accredited laboratories of NantOmics.
Key benefits of the Working Group branches of study include:
- Physicians and professionals bring their expertise and combined years of knowledge and understanding from within a specific disease study to the collective;
- Integrated research;
- Real-time communication of current data;
- Access to the most cutting edge technology available in immunotherapy research to date; and,
- A keen familiarity with the special needs of patients with specific cancers
“Building a collaborative group of thought leaders and visionaries who are committed to fighting breast cancer is essential to the overall efforts of Cancer MoonShot 2020,” explained Patrick Soon-Shiong, M.D., founder and CEO of NantWorks and leader of the Cancer MoonShot 2020 program. “I am thrilled that this group of experts have joined forces to work together to ensure that development of next generation diagnostics and combination immunotherapies will be accelerated to transform the way breast cancer is treated.”
more recommended stories
Mexican student accepted in NASA’s Space Program for the third time
Felipe Ávila Gómez is a Mexican.
Migrant Boy, 3, Swept Away With His Mom in the Rio Grande
U.S. Border Patrol agents are searching.
Mexico’s Economy Secretariat will close representations in 6 countries
To comply with the AMLO government’s.
Progreso registers record figures during this summer holiday season
The Malecón of Progreso had a.
Dog killed in drive by shooting in Tekax
Just because “they didn’t like him”,.
US political and economical arena on fire!
Trump tweets: ‘Who is our bigger.
“The Chosen One” by Clay Jones – Opinion
Defending your leader’s comments with, “he.
Three more stations added to the Maya Train Route (FONATUR)
According to Rogelio Jiménez Pons, director.
Migraine in Mexico generates multimillion annual losses
Having a migraine causes disabilities in.
Mexican govenment fines Cancun airport $3.7 million USD for taxi monopoly
MEXICO CITY (AP) — Mexico’s anti-monopoly.